Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis.
Pratyusha ChitturiShiwen XuBahja Ahmed AbdiJohn NguyenDavid E CarterSarthak SinhaRohit AroraJeff BiernaskieRichard J StrattonAndrew LeaskPublished in: Annals of the rheumatic diseases (2023)
Our data clarify niches within the skin activated in fibrosis and suggest that compounds, such as celastrol, that antagonise the YAP pathway may be potential treatments for SSc skin fibrosis.